• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.

作者信息

Kelloff Gary J, O'Shaughnessy Joyce A, Gordon Gary B, Hawk Ernest T, Sigman Caroline C

机构信息

National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biomedical Imaging Program, Bethesda, Maryland 20892, USA.

出版信息

Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):593-6.

PMID:12869396
Abstract
摘要

相似文献

1
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.反驳观点：由于一些替代终点生物标志物可测量肿瘤形成过程，因此它们在开发针对散发性癌症的癌症化学预防剂方面将具有很高的实用性。
Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):593-6.
2
Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.观点：替代终点生物标志物在开发针对散发性癌症的癌症化学预防药物方面的作用可能有限。
Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):589-92.
3
Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.用于II期癌症化学预防试验的替代终点生物标志物。
J Cell Biochem Suppl. 1994;19:1-9.
4
Surrogate end-point biomarkers in chemopreventive drug development.化学预防药物研发中的替代终点生物标志物
IARC Sci Publ. 2001;154:13-26.
5
Biomarkers and surrogacy: relevance to chemoprevention.生物标志物与替代指标：与化学预防的相关性
IARC Sci Publ. 2001;154:27-47.
6
Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.降低癌症风险药物研发中替代终点的观点
Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):127-37.
7
Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia.癌症化学预防剂临床试验替代终点生物标志物的开发：与侵袭前（上皮内）肿瘤形成基本特性的关系
J Cell Biochem Suppl. 1994;19:10-22.
8
Increasing the power of surrogate endpoint biomarkers: the aggregation of predictive factors.增强替代终点生物标志物的效能：预测因素的整合
J Cell Biochem Suppl. 1994;19:278-82.
9
Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.II期临床试验中候选化学预防化合物结肠生物标志物研究的建议总结。
J Cell Biochem Suppl. 1994;19:94-8.
10
The convergent development of molecular-targeted drugs for cancer treatment and prevention.用于癌症治疗和预防的分子靶向药物的趋同发展。
Clin Cancer Res. 2007 Jul 15;13(14):4035-41. doi: 10.1158/1078-0432.CCR-07-0063.

引用本文的文献

1
Mitochondrial and nuclear genomics and the emergence of personalized medicine.
Hum Genomics. 2012 Jul 5;6(1):3. doi: 10.1186/1479-7364-6-3.
2
The effectiveness of chemoprevention agents is underestimated when lesion sizes are rounded.当病变大小四舍五入时，化学预防剂的效果被低估了。
Cancer Prev Res (Phila). 2010 Feb;3(2):136-9. doi: 10.1158/1940-6207.CAPR-09-0114. Epub 2010 Jan 19.
3
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.非甾体抗炎药可调节CDKN2A、TP53以及进展为食管腺癌的DNA含量风险。
PLoS Med. 2007 Feb;4(2):e67. doi: 10.1371/journal.pmed.0040067.